Dealroom · Jul 2026
Reports a $2.06M NIAAA grant for IND-enabling work on a TERT mRNA therapy for alcoholic hepatitis, following prior regulatory progress and earlier awards.
We extend telomeres to extend the human health span
Company research
Public company, workplace, funding, and market signals
Overview
Mountain View biotech developing transient TERT mRNA therapeutics in proprietary lipid nanoparticles to extend telomeres and reverse cellular aging. Public sources conflict on founding year (2016 vs 2018); using 2018 from the company’s LinkedIn/Y Combinator profile, while older directories list 2016.
Primary product
TERT mRNA lipid nanoparticle therapeutics for telomere extension
Founded
2018
Headquarters
Mountain View, CA 94043, United States
Team size
10-20 employees
Industry
Biotechnology
Sub-industry
Longevity biotech / mRNA therapeutics
Offices
Mountain View, CA 94043, United States
Business model
therapeutic drug development
research reagent sales
clinical research collaboration
potential partnering / licensing
Funding
Stage
seed
Total raised
$17.4M
Latest round
NIAAA SBIR Commercialization Readiness Pilot grant · Jul 2026
Latest amount
$2.1M
People & investors
Leadership
Founder & CEO
Founder & COO
Chief Medical Officer (Part-time)
Director of Finance and Administration
Head of Immunology Research
Head of Partnerships & Investor Relations
Guo Tao
Director, Scientific Research
Victor Knopov
Chemistry, Manufacturing, and Controls (CMC)
Work & culture
Mission-driven translational biotech with a fast-paced startup feel; public materials emphasize collaboration, clinical translation, and building toward upcoming trials.
Product & market
Differentiators
- —Transient TERT mRNA rather than permanent telomerase activation
- —Proprietary lipid nanoparticle delivery platform
- —Multiple organ-system programs with tissue-targeted delivery
- —Research-use reagent product (TeloAid)
- —Clinical-stage translational programs supported by SBIR awards
Technology
modified mRNA
TERT mRNA
lipid nanoparticles (LNPs)
telomerase activation
targeted mRNA delivery
telomere extension
biomarker tracking
Customers
patients with pulmonary fibrosis
patients with chronic liver disease / alcoholic hepatitis
patients with bone marrow failure and related hematologic disorders
academic and industry research collaborators
research labs purchasing TeloAid
Competitors
CAMP4 Therapeutics
OncoHost
Abogen Biosciences
Scale & contact
Estimated revenue
under $1M
Latest news
EIN Presswire · Jan 2024
Announces a manufacturing collaboration with Kudo Biotechnology to develop one of Rejuvenation’s RNA drug candidates.
Business Wire · Sep 2023
Announced a $10.6M seed financing led by Khosla Ventures and $4.6M in grant funding, bringing total reported funding to $15.2M.
Longevity.Technology · Sep 2023
Covers the seed round, investors, grant funding, and the company’s telomere-extension platform and disease targets.
Jobs and careers at Rejuvenation Technologies Inc.
0 jobs at Rejuvenation Technologies Inc.
No open positions
Check back later for new openings